Limited Competition for the Continuation of the Consortium for Radiologic Imaging

放射成像联盟延续的有限竞争

• 批准号: 9044528
• 负责人: ARLENE B CHAPMAN
• 金额: $ 33.15万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-06-01 至 2017-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9044528
• 关键词: Address; Affect; Age; Alabama; Ancillary Study; Autosomal Dominant Polycystic Kidney; Biological; Biological Markers; Characteristics; Clinic; Clinical; Clinical Data; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Counseling; Cyst; Cystic kidney; DNA; Data; Data Analyses; Development; Diet; Disease Progression; End stage renal failure; Family member; Funding; Genetic; Genetic study; Genotype; Goals; Growth; Hepatic Cyst; Image; Individual; Intake; Intervention; Kansas; Kidney; Kidney Diseases; Kidney Failure; Life Expectancy; Liver; Magnetic Resonance; Magnetic Resonance Imaging; Measurement; Methods; Modeling; Morbidity - disease rate; National Institute of Diabetes and Digestive and Kidney Diseases; Nature; Other Genetics; Participant; Patient Outcomes Assessments; Patients; Pattern; Phenotype; Pilot Projects; Polycystic Kidney Diseases; Population; Predictive Value; Principal Investigator; Proteomics; Quality of life; Renal Blood Flow; Research Personnel; Resources; Risk; Risk Factors; Role; Sampling; Sensitivity and Specificity; Severities; Severity of illness; Sodium; Surrogate Markers; Testing; Universities; Washington; base; drug development; follow-up; genetic risk factor; improved; modifiable risk; predictive marker; programs; repository; serological marker; sex; urinary

DESCRIPTION (provided by applicant): Autosomal dominant polycystic kidney disease (ADPKD) is a major cause of morbidity and is the fourth leading cause of ESRD in the world, affecting more than 500,000 U.S. citizens. Researchers at the University of Alabama, Emory University, University of Kansas, Mayo Clinic and Washington University joined together in 2000 to create the Consortium for Radiologic Studies of Polycystic Kidney Disease (CRISPI) and in 2006 included the University of Pittsburgh in place of Washington University for CRISP II. The primary objectives of CRISPI and II were to: establish accurate, reliable and reproducible magnetic resonance based measurements of total kidney volume (TKV), liver cyst volume (LCV), renal blood flow (RBF), and patterns of cyst growth and expansion. Based on 7.3 years of longitudinal followup in 200 CRISP l/ll participants, we can now 1) establish an uniquivocal relationship between TKV and qualitative (patient reported outcomes) and quantitative (renal insufficiency) end-points; as well as 2) identify potential modifiable risk factors associating with TKV and LCV to intervene upon. TKV ultimately may be used as a surrogate marker of disease progression in clinical trials. The goals of CRISPIN extend the observations of CRISPI/II. The overarching Aim for CRISP III is to develop and enhance prediction models that best predict renal insufficiency in ADPKD. Specifically, Aim 1: Extend the serial quantification of TKV and LCV to develop and test new models for predicting the risk of developing renal insufficiency. Aim 2: Determine the extent to which age and sex-adjusted measurements of RBF predict the rate of change in TKV and determine if RBF and TKV independently predict the risk of developing renal insufficiency. Aim 3: Develop methods to quantify the influence of renal cyst number, volume, and topography at baseline on the subsequent course of TKV and GFR and the risk of developing renal insufficiency. Aim 4: Expand and analyze CRISP biological samples to improve genotype/phenotype and biomarker studies. Aim 5. Determine whether intensive dietary counseling and intervention in a small group of CRISP participants is successful in modifying the relatively fixed pattern of sodium intake observed in CRISPI and reducing the rate of growth of the polycystic kidneys.

描述(申请人提供)：常染色体显性遗传性多囊肾病(ADPKD)是发病率的主要原因，是世界上ESRD的第四大原因，影响着50多万美国公民。阿拉巴马大学、埃默里大学、堪萨斯大学、梅奥诊所和华盛顿大学的研究人员于2000年联合成立了多囊肾病放射学研究联盟(Crispi)，并于2006年将匹兹堡大学取代华盛顿大学用于CRISP II。Crispi和II的主要目标是：建立基于磁共振的准确、可靠和可重复性的肾脏总体积(TKV)、肝囊肿体积(LCV)、肾血流(RBF)以及囊肿生长和扩张模式的测量。基于对200名CRISE L/11参与者7.3年的纵向随访，我们现在可以1)建立TKV与定性(患者报告的结果)和定量(肾功能不全)终点之间的独特关系；以及2)确定与TKV和LCV相关的潜在可修改风险因素进行干预。在临床试验中，TKV最终可能被用作疾病进展的替代标记物。CRISPIN的目标扩展了Crispi/II的观察。CRISP III的首要目标是开发和增强最好地预测ADPKD肾功能不全的预测模型。具体地说，目标1：扩展TKV和LCV的连续量化，以开发和测试预测发生肾功能不全风险的新模型。目的2：确定年龄和性别调整的RBF测量预测TKV变化率的程度，并确定RBF和TKV是否独立预测发生肾功能不全的风险。目的3：建立量化基线时肾囊肿数量、体积和地形图对TKV和GFR后续病程的影响以及发生肾功能不全风险的方法。目的4：扩大和分析脆性生物样本，以改进基因/表型和生物标记物研究。目的5.确定在一小群CRISPI参与者中进行强化饮食咨询和干预是否成功地改变了CRISPI中观察到的相对固定的钠摄取模式，并降低了多囊肾的生长速度。